Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
Notes underwriting agrmnt
|
|
Allarity Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/15/2022 |
8-K
| Quarterly results|
Docs:
|
"Allarity Therapeutics Reports Third Quarter 2022 Financial Results Cambridge, MA U.S.A. — Allarity Therapeutics, Inc. , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022. Balance Sheet: As of September 30, 2022, Allarity’ s cash was $3.9 million, as compared to $19.6 million as of December 31, 2021. R&D Expenses: Research and Development expenses were $3.0 million for the three months ended September 30, 2022, as compared to $1.4 million for the three months ended September 30, 2021. G&A Expenses: General and Administrative expenses were $1.6 million for the three months ended September 30, 2022, as c..." |
|
| 10/11/2022 |
8-K
| Quarterly results |
| 05/27/2022 |
8-K
| Quarterly results |
|
|